- Home
- YQ vs PULM Comparison
YQ vs PULM Comparison
Compare YQ & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YQ
- PULM
- Stock Information
- Founded
- YQ 2012
- PULM 2003
- Country
- YQ China
- PULM United States
- Employees
- YQ N/A
- PULM N/A
- Industry
- YQ Other Consumer Services
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- YQ Real Estate
- PULM Health Care
- Exchange
- YQ Nasdaq
- PULM Nasdaq
- Market Cap
- YQ 19.4M
- PULM 20.5M
- IPO Year
- YQ 2020
- PULM N/A
- Fundamental
- Price
- YQ $1.90
- PULM $5.33
- Analyst Decision
- YQ
- PULM
- Analyst Count
- YQ 0
- PULM 0
- Target Price
- YQ N/A
- PULM N/A
- AVG Volume (30 Days)
- YQ 44.6K
- PULM 9.0K
- Earning Date
- YQ 09-03-2025
- PULM 08-12-2025
- Dividend Yield
- YQ N/A
- PULM N/A
- EPS Growth
- YQ N/A
- PULM N/A
- EPS
- YQ N/A
- PULM N/A
- Revenue
- YQ $25,546,613.00
- PULM $1,921,000.00
- Revenue This Year
- YQ N/A
- PULM N/A
- Revenue Next Year
- YQ N/A
- PULM $134.88
- P/E Ratio
- YQ N/A
- PULM N/A
- Revenue Growth
- YQ N/A
- PULM N/A
- 52 Week Low
- YQ $1.26
- PULM $1.78
- 52 Week High
- YQ $3.19
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- YQ 35.80
- PULM 33.68
- Support Level
- YQ $1.85
- PULM $5.20
- Resistance Level
- YQ $2.23
- PULM $5.77
- Average True Range (ATR)
- YQ 0.14
- PULM 0.29
- MACD
- YQ -0.05
- PULM -0.03
- Stochastic Oscillator
- YQ 7.94
- PULM 9.93
About YQ 17 Education & Technology Group Inc.
17 Education & Technology Group Inc is an education technology company in China. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).